Literature DB >> 15340747

A case of familial tumoral calcinosis in a neonate and review of the literature.

Elias P Polykandriotis1, Florenz K Beutel, Raymund E Horch, Jörg Grünert.   

Abstract

BACKGROUND: Tumoral calcinosis occurs in two distinct clinical forms. The sporadic form is secondary to chronic renal failure, hyperparathyroidism, milky-alkali syndrome, hypervitaminosis D and other systemic disorders. The familial form is extremely rare (around 100 cases worldwide) and affects patients in the first or second decade of life. It is believed to be transmitted in a dominant autosomal manner with variable clinical expressivity and is manifested as hyperphosphatemia, elevated serum 1,25-dihydroxyvitamin D with juxta-articular tumorous calcifications. Moreover, the theory of a unique dental malformation serving as a screening marker for clinically non-apparent affected individuals is revisited and reconfirmed. CASE REPORT: We present a case of a Caucasian male newborn, as well as a review of the literature with differential diagnostic considerations and their therapeutical implications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15340747     DOI: 10.1007/s00402-004-0715-0

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  14 in total

1.  A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.

Authors:  Ilana Chefetz; Raoul Heller; Assimina Galli-Tsinopoulou; Gabriele Richard; Bernd Wollnik; Margarita Indelman; Friederike Koerber; Orit Topaz; Reuven Bergman; Eli Sprecher; Eckhard Schoenau
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

2.  Tumoral calcinosis--or is it? A case report and review.

Authors:  Warren C Hammert; Leroy R Lindsay
Journal:  Hand (N Y)       Date:  2008-09-19

3.  FGF23 Is Not Required to Regulate Fetal Phosphorus Metabolism but Exerts Effects Within 12 Hours After Birth.

Authors:  Yue Ma; Beth J Kirby; Nicholas A Fairbridge; Andrew C Karaplis; Beate Lanske; Christopher S Kovacs
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

Review 4.  Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.

Authors:  M Chakhtoura; M S Ramnitz; N Khoury; G Nemer; N Shabb; A Abchee; A Berberi; M Hourani; M Collins; S Ichikawa; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2018-06-20       Impact factor: 4.507

5.  A rare disorder: tumoral calcinosis and cirrhosis.

Authors:  Seyyed Farshad Allameh; Akram Ghadiri Anari; Mehrnaz Asadi Gharabaghi; Manouchehr Nakhjavani
Journal:  BMJ Case Rep       Date:  2011-08-17

6.  Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification.

Authors:  Eli Sprecher
Journal:  J Invest Dermatol       Date:  2009-10-29       Impact factor: 8.551

Review 7.  Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.

Authors:  Nobuaki Ito; Seiji Fukumoto
Journal:  Calcif Tissue Int       Date:  2020-01-22       Impact factor: 4.333

Review 8.  Hydroxyapatite crystal deposition forming para-articular multiple large masses: a case report and literature review.

Authors:  Baihai Su; Yuanjiao Tang; Yi Tang; Li Qiu
Journal:  Rheumatol Int       Date:  2012-12-21       Impact factor: 2.631

9.  Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis.

Authors:  Lihao Sun; Lin Zhao; Lianjun Du; Peipei Zhang; Minjia Zhang; Min Li; Tingting Liu; Lei Ye; Bei Tao; Hongyan Zhao; Jianmin Liu; Xiaoyi Ding
Journal:  Bone Res       Date:  2016-11-08       Impact factor: 13.567

Review 10.  Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.

Authors:  Silje Rafaelsen; Stefan Johansson; Helge Ræder; Robert Bjerknes
Journal:  BMC Genet       Date:  2014-09-24       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.